| Compound | BPC-157 + TB-500 |
|---|---|
| Category | Vendor blend (healing peptides) |
| Class | Healing and Anti-Inflammatory Peptides |
| Evidence tier | Minimal evidence |
| WADA status | Not individually listed; verify current status if subject to testing |
| Sold on this site | No — this is a reference database |
Overview
BPC-157 + TB-500 — a vendor blend (healing peptides) — sits in the "Minimal evidence" tier of this catalog. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
A combination product pairing BPC-157 with TB-500, sold by research-compound vendors. The combination itself has never been evaluated in a published human trial.
Mechanism of Action
The rationale is purely mechanistic stacking: BPC-157’s proposed tissue-repair signaling combined with thymosin beta-4 fragment activity. There are no data addressing whether the two interact.
Research and Evidence
No clinical evidence exists for the combination; the underlying compounds each rest on preclinical work of debated quality. Combination claims are marketing, not evidence.
Safety and Side Effects
Unverified composition and sterility compound the baseline uncertainty of both ingredients. Blends add dose ambiguity — two active compounds, one unlabeled ratio.
Frequently Asked Questions
What is the evidence tier of BPC-157 + TB-500?
BPC-157 + TB-500 is graded "Minimal evidence" on this site. There is little or no formal study of this compound. Claims rest on anecdote, theory, or very early-stage work; risk data are absent by definition.
Is BPC-157 + TB-500 an approved medicine?
No. Minimal evidence means the compound has not reached universal regulatory approval; the tier description above explains exactly what level of evidence exists.
Where can I read the primary studies for BPC-157 + TB-500?
The references section at the end of this entry links the key primary sources — regulator labels, trial registrations, and peer-reviewed papers. Our "How to Read a Peptide Study" guide explains how to evaluate them.
References
- ClinicalTrials.gov — no combination trials registered. [source]
Evidence tier: Minimal evidence · Last reviewed: 2026-09-05 · Sources cited below.